{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:19:51Z","timestamp":1768562391651,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11845-011-0790-5","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:34:00Z","timestamp":1325810040000},"page":"237-242","source":"Crossref","is-referenced-by-count":23,"title":["A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?"],"prefix":"10.1007","volume":"181","author":[{"given":"J. E.","family":"O\u2019Connell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ikeagwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"790_CR1","unstructured":"Merck &Co, Inc: Regarding Fosamax (alendronate sodium) and rare cases of osteonecrosis of the jaw. Available at: http:\/\/www.merck.com\/newsroom\/press_releases\/product\/fosamax_statement"},{"key":"790_CR2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","volume":"2","author":"CAL Bassett","year":"1969","unstructured":"Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Diphosphonates in the treatment of myositis ossificans. Lancet 2:845","journal-title":"Lancet"},{"key":"790_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","volume":"1","author":"R Smith","year":"1971","unstructured":"Smith R, Russell RGG, Bishop M (1971) Diphosphonates and Pagets disease of bone. Lancet 1:945\u2013947","journal-title":"Lancet"},{"key":"790_CR4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","volume":"289","author":"RD Altman","year":"1973","unstructured":"Altman RD, Johnston CC, Khari MRA, Wellma H, Scrafini AN, Sankey RR (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Pagets disease of bone (osteitis ossificans). N Eng J Med 289:1379\u20131382","journal-title":"N Eng J Med"},{"key":"790_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archinte.1991.00400030039007","volume":"151","author":"FR Singer","year":"1991","unstructured":"Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E et al (1991) Treatment of hypercalcaemia of malignancy with intravenous etidronate: a controlled multicentre study. Arch Intern Med 151:471\u2013476","journal-title":"Arch Intern Med"},{"key":"790_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0221-8747(81)90050-3","volume":"3","author":"GAM Finerman","year":"1981","unstructured":"Finerman GAM, Stover SL (1981) Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Rel Res 3:337\u2013342","journal-title":"Metab Bone Dis Rel Res"},{"key":"790_CR7","unstructured":"Chilton HM, Francis MD, Thrall JH (1990) In: Swanson DP, Chilyon, Thrall JH (eds.) Pharmaceuticals in medical imaging. McMillan Publishing Company, New York, pp 537\u2013563"},{"key":"790_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73\u201379","journal-title":"N Engl J Med"},{"key":"790_CR9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK (1999) Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"issue":"(Suppl.2)","key":"790_CR10","first-page":"S230","volume":"17","author":"S Boonen","year":"2006","unstructured":"Boonen S, Delmas PD, Wenderoth D et al (2006) Risedronate shown to be safe and effective in men with osteoporosis in a 2\u00a0year, double blind, randomized, placebo controlled, multicentre study. Osteoporos Int 17((Suppl.2)):S230\u2013S231","journal-title":"Osteoporos Int"},{"key":"790_CR11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"790_CR12","unstructured":"Irish Medicines Board (2010) Bisphosphonates and osteonecrosis of the jaws: update on risk minimisation including new recommendations on preventive dental measures. Issue 35"},{"key":"790_CR13","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate Related Osteonecrosis of the Jaws (2007) American association of oral and maxillofacial surgeons position paper on BRONJ. J Oral Maxillofac Surg 65:369","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"790_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BGM Durie","year":"2005","unstructured":"Durie BGM, Katz M, Crowley J (2005) Osteonecrosis of the jaws and bisphosphonates (letter). N Eng J Med 353:99","journal-title":"N Eng J Med"},{"key":"790_CR15","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580","journal-title":"J Clin Oncol"},{"key":"790_CR16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B et al (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A Badros","year":"2006","unstructured":"Badros A, Weikel D, Salama A et al (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945","journal-title":"J Clin Oncol"},{"key":"790_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","volume":"66","author":"JH Wessel","year":"2008","unstructured":"Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826","journal-title":"J Bone Miner Res"},{"key":"790_CR20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","volume":"92","author":"M Khamaisi","year":"2007","unstructured":"Khamaisi M, Regev E, Yarom N et al (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92:1172","journal-title":"J Clin Endocrinol Metab"},{"key":"790_CR21","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","volume":"112","author":"ME Sarasquete","year":"2008","unstructured":"Sarasquete ME, Garcia-Sainz R, Marin L et al (2008) Bisphosphonate related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709","journal-title":"Blood"},{"key":"790_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","volume":"67","author":"S Lehrer","year":"2009","unstructured":"Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M et al (2009) Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesised candidate gene. J Oral Maxillofac Surg 67:159\u2013161","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"790_CR23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","volume":"67","author":"ER Carlson","year":"2009","unstructured":"Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(Suppl 1):85\u201395","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum ctx testing, prevention and treatment. J Oral Maxillofac Surg 65:2397","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.joms.2007.03.019","volume":"65","author":"JJ Freiberger","year":"2007","unstructured":"Freiberger JJ, Padilla-Burgos R, Chhoeu AU (2007) Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65:1321","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.joms.2006.05.042","volume":"64","author":"P Vescovi","year":"2006","unstructured":"Vescovi P, Merigo E, Meleti M et al (2006) Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment (Letter). J Oral Maxillofac Surg 64:1460","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"790_CR27","first-page":"2","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Landesberg R, Mehrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J Oral Maxillofac Surg 67(Suppl 1):2\u201312","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR28","volume-title":"Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, prevention and treatment","author":"RE Marx","year":"2007","unstructured":"Marx RE (2007) Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, prevention and treatment. Quintessence Publishing, Hanover Park"},{"key":"790_CR29","doi-asserted-by":"crossref","unstructured":"Rosen HN, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100\u2013103","DOI":"10.1007\/PL00005830"},{"key":"790_CR30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","volume":"67","author":"R Kunchur","year":"2009","unstructured":"Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167\u20131173","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"790_CR31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"76","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 76(Suppl 1):61\u201370","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","volume":"13","author":"R Hannon","year":"1998","unstructured":"Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124\u20131133","journal-title":"J Bone Miner Res"},{"key":"790_CR33","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","volume":"67","author":"YD Kwon","year":"2009","unstructured":"Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C (2009) Correlation between serum C-terminal cross-linking telopeptide of type 1 collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644\u20132648","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","volume":"44","author":"JV Bagan","year":"2008","unstructured":"Bagan JV, Jimenez Y, Gomez D, Sirera R, Poveda R, Scully C (2008) Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44:1088\u20131089","journal-title":"Oral Oncol"},{"issue":"Suppl 1","key":"790_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.joms.2009.01.003","volume":"67","author":"LA Assael","year":"2009","unstructured":"Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risk, and preventative strategies. J Oral Maxillofac Surg 67(Suppl 1):35\u201343","journal-title":"J Oral Maxillofac Surg"},{"key":"790_CR36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.joms.2009.08.014","volume":"68","author":"AN Goss","year":"2010","unstructured":"Goss AN (2010) Letter to the editor. J Oral Maxillofac Surg 68:488","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Irish Journal of Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-011-0790-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-011-0790-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-011-0790-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T23:31:35Z","timestamp":1561159895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-011-0790-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1007\/s11845-011-0790-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,6]]}}}